ライフサイエンスコーパス: were eligible

1 spected advanced-stage ovarian cancer who qualified for PCS were eligible.

2 CIDP who responded to intravenous immunoglobulin treatment were eligible.

3 istologic findings and BI-RADS 3 masses stable at 12 months were eligible.

4 d States or Puerto Rico who had a sister with breast cancer were eligible.

5 or less at 18 weeks 0 days to 23 weeks 6 days of gestation were eligible.

6 4, and December 31, 2015, with Lenstar 900 optical biometry were eligible.

7 lusters, households with a child under the age of 4.5 years were eligible.

8 was delivered to pre-registration healthcare professionals were eligible.

9 fraction [EF] <50%) but without severe valvular dysfunction were eligible.

10 During the 20-month period, 214 patients were eligible, 182 were approached, and 32 missed.

11 rs randomly assigned to immediate vaccination (of whom 3232 were eligible, 2151 consented, and 2119 were immediately vacc

12 ters randomly assigned to delayed vaccination (of whom 3096 were eligible, 2539 consented, and 2041 were vaccinated 21 da

13 ividuals screened (from August 2013 to September 2014), 260 were eligible and 78 were enrolled (mean [SD] age, 16.5 [0.73

14 It included 33 177 patients under age 65 who were eligible and due for CRC screening and managed by the pa

15 or were unavailable to be interviewed, 4% refused, and 80% were eligible and participated.

16 Nov 2, 2012, and Feb 4, 2016, we screened 587 patients; 357 were eligible and randomly assigned to receive placebo (n=73)

17 All surgical departments were eligible for a financial incentive if they met a 5% cost

18 A total of 15,144 admissions (10%) were eligible for analysis once predefined exclusion criteria

19 according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission.

20 s developed for patients with inoperable, localized HCC who were eligible for both RFA and SBRT to evaluate the cost-effe

21 rs) underwent NASH FibroSure testing during MTX therapy and were eligible for correlation analysis.

22 Patients of all ages with a diagnosis of BCNS were eligible for enrollment.

23 r dysfunction (ejection fraction</=48%) >/=4 days poststent were eligible for enrollment.

24 d for elective open lobectomy or bilobectomy for malignancy were eligible for enrollment.

25 Patients were eligible for inclusion as age-matched controls if they w

26 underwent full screening and data extraction, and 14 trials were eligible for inclusion in the review.

27 , 2015, 31 497 patients were recruited, and 24 736 patients were eligible for inclusion in this analysis.

28 ble BCR-ABL1 transcripts for the 2 preceding years at least were eligible for inclusion.

29 ka University Hospital, Stockholm, Sweden from 2011 to 2014 were eligible for inclusion.

30 patients with a likely or confirmed diagnosis of PSP or MSA were eligible for inclusion.

31 Of the 38 544 studies initially identified, 52 were eligible for inclusion.

32 or any studied randomized controlled trial and 30% (n = 28) were eligible for only one of the 15.

33 2011 through 2013 to evaluate the number of hospitals that were eligible for penalties, in that they met a volume thresh

34 n (M3) initiative using a convenience sampling approach and were eligible for pooling given adequate ethical approval and

35 2002, and Oct 8, 2010, 1347 patients were enrolled and 676 were eligible for random allocation, 598 (88%) of whom were r

36 screening and 16 original studies (1327 eyes, 787 patients) were eligible for review.

37 healthy participants (65% men; mean age, 47.4+/-9.9 years) were eligible for speckle tracking analysis.

38 Of these, 58 individuals were eligible for the FABS-5+ study, could be located, and ag

39 Adults (aged >/=18 years) were eligible for the study if they had pathologically confir

40 Of 71 patients enrolled in AURA, 53 were eligible for this analysis.

41 l Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, dose-escalation trial.

42 Patients were eligible for this randomised, double-blind, placebo-cont

43 er concurrent patients at the MD Anderson Cancer Center who were eligible for this trial but declined to participate or h

44 (1:1) HIV-infected, ART-naive children aged 0-12 years who were eligible for treatment to receive ART within 48 h (urgen

45 s in 4 countries from 2014 to 2016, consecutive outpatients were eligible if they had >/=1 of the following: chest/abdomi

46 Patients were eligible if they had an ankle-brachial index (ABI) of 0.

47 Cohorts were eligible if they had publicly available GEP data from pa

48 Patients were eligible if they received combination therapy for >/=48

49 Patients were eligible if they were at least aged 18 years, had Easter

50 Patients who were eligible patients were randomly assigned (1:1) via permu